Not that I want to contradict you Ohm. I do believe their is a whole lot of risk in a reduced amount of patients in the trial. It’s scary to assume we will get p value.

Maybe they are using some inside information we don’t quite know about. Some Philippines information that hasn’t been released to the public? That’s my hope anyway. Blind changes without data to prove why you made the change would be reckless and would not be viewed by the investors as a good move.

Let’s hope he can explain a little better why he made this decision when we are/we’re set up to succeed in our current size trial. I sincerely hope he can back up his decision with facts and data.

I hope like the rest of us to see something great with increased dosing and extended time to see Leronlimab work in our Critical trial and Severe trial. Time will tell.